| Cerebrotendinous xanthomatosis (CTX): a treatable lipid storage disease. | |
| | |
MedLine Citation:
|
PMID: 19696711 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive lipid storage disease with multi-organ involvement. The clinical manifestations usually start at infancy and develop during the first and second decades of life; infantile-onset diarrhea may be the earliest clinical manifestation of CTX. Additional clinical manifestations are juvenile cataracts, tendon xanthomas, and multiple progressive neurological symptoms. Systemic manifestations that are often found include osteoporosis, heart involvement and premature arteriosclerosis. CTX is caused by mutations in the sterol 27 hydroxylase gene (CYP27) on chromosome 2q35-qter, which is responsible for conversion of cholesterol to cholic and chenodeoxycholic acid. Reduced synthesis of cholic and chenodeoxycholic acid results in failed feedback inhibition of cholesterol production, which in turn leads to increased serum cholestanol concentration and elevated urinary bile alcohols. Early treatment with chenodeoxycholic acid (CDCA) prevents the clinical symptoms and prevents deterioration. Although CTX is rare world wide, genetic islands of high frequency have been reported. In this review we would like to familiarize the reader with this fatal inborn error of metabolism that is possibly under-diagnosed and is preventable once recognized and treated. |
| | |
Authors:
|
Zohar Keren; Tzipora C Falik-Zaccai |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Pediatric endocrinology reviews : PER Volume: 7 ISSN: 1565-4753 ISO Abbreviation: Pediatr Endocrinol Rev Publication Date: 2009 Sep |
Date Detail:
|
Created Date: 2009-08-21 Completed Date: 2009-09-30 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101202124 Medline TA: Pediatr Endocrinol Rev Country: Israel |
Other Details:
|
Languages: eng Pagination: 6-11 Citation Subset: IM |
Affiliation:
|
Institute of Human Genetics, Western Galilee Hospital, Naharia, Israel. kzohar76@gmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Chenodeoxycholic Acid / therapeutic use Cytochrome P-450 CYP27A1 / deficiency, genetics Gastrointestinal Agents / therapeutic use Genetic Counseling Genetic Screening Humans Mutation Treatment Outcome Xanthomatosis, Cerebrotendinous / diagnosis*, drug therapy*, enzymology, genetics |
| Chemical | |
Reg. No./Substance:
|
0/Gastrointestinal Agents; 474-25-9/Chenodeoxycholic Acid; EC 1.14.-/Cytochrome P-450 CYP27A1 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Drugs for inflammatory bowel disease.
Next Document: Sex differentiation disorders (SDD) prenatal sonographic diagnosis, genetic and hormonal work-up.